5-Lipoxygenase gene disruption reduces amyloid-β pathology in a mouse model of Alzheimer's disease

FASEB Journal

Volumn 22, Issue 4, 2008, Pages 1169-1178

  Firuzi, Omidreza ^a   Zhuo, Jiamin ^a   Chinnici, Cinzia M ^a   Wisniewski, Thomas ^b   Praticò, Domenico ^a,c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

secretase; A ; Amyloid precursor protein; Leukotrienes; Tg2576

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ARACHIDONATE 5 LIPOXYGENASE; GAMMA SECRETASE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN LEVEL; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE DISRUPTION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; METABOLITE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROCESSING; TRANSGENIC MOUSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, TRANSGENIC; RECEPTORS, CELL SURFACE; UP-REGULATION;

MUS; MUS MUSCULUS;

EID: 42049114647     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.07-9131.com     Document Type: Article

References (38)

1. Selkoe, D. J. (2002) Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J. Clin. Invest. 110, 1375-1381
2. Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., and Binder, L. I. (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83, 4913-4917
3. Wyss-Coray, T. (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005-1015
4. Funk, C. D. (2001) Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 294, 1871-1875
5. Yermakova, A. V., and O'Banion, M. K. (2001) Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol. Aging 22, 823-836
6. Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D., Trojanowski, J. Q., Lee, V. M., and Pratico, D. (2004) Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 165, 2197-2206
7. Liang, X., Wang, Q., Hand, T., Wu, L., Breyer, R. M., Montine, T. J., and Andreasson, K. (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J. Neurosci. 25, 10180-10187
8. Firuzi, O., and Pratico, D. (2006) Coxibs and Alzheimer's disease: should they stay or should they go? Ann. Neurol. 59, 219-228
9. Yao, Y., Clark, C. M., Trojanowski, J. Q., Lee, V. M., and Pratico, D. (2005) Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann. Neurol. 58, 623-626
10. Pratico, D., Zhukareva, V., Yao, Y., Uryu, K., Funk, C. D., Lawson, J. A., Trojanowski, J. Q., and Lee, V. M. (2004) 12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. Am. J. Pathol. 164, 1655-1662
11. Mhatre, M. (2006) The role of the 5-lipoxygenase pathway in Alzheimer's disease. Drugs Future 31, 83-89
12. Chinnici, C. M., Yao, Y., and Pratico, D. (2006) The 5-lipoxygenase enzymatic pathway in the mouse brain: Young versus old. Neurobiol. Aging 28, 1457-1462
13. Uz, T., Pesold, C., Longone, P., and Manev, H. (1998) Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J. 12, 439-449
14. Lammers, C. H., Schweitzer, P., Facchinetti, P., Arrang, J. M., Madamba, S. G., Siggins, G. R., and Piomelli, D. (1996) Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J. Neurochem. 66, 147-152
15. Morris, A. A., and Rodger, I. W. (1998) Leukotrienes and the brain. Lancet 352, 1487-1488
16. Piomelli, D. (1994) Eicosanoids in synaptic transmission. Crit. Rev. Neurobiol. 8, 65-83
17. Manev, H., Uz, T., and Qu, T. (1998) Early upregulation of hippocampal 5-lipoxygenase following systemic administration of kainate to rats. Restor. Neurol. Neurosci. 12, 81-85
18. Simmet, T., and Tippler, B. (1990) Cysteinyl-leukotriene production during limbic seizures triggered by kainic acid. Brain Res. 515, 79-86
19. Zhou, Y., Wei, E. Q., Fang, S. H., Chu, L. S., Wang, M. L., Zhang, W. P., Yu, G. L., Ye, Y. L., Lin, S. C., and Chen, Z. (2006) Spatio-temporal properties of 5-lipoxygenase expression and activation in the brain after focal cerebral ischemia in rats. Life Sci. 79, 1645-1656
20. Drazen, J. M., Yandava, C. N., Dube, L., Szczerback, N., Hippensteel, R., Pillari, A., Israel, E., Schork, N., Silverman, E. S., Katz, D. A., and Drajesk, J. (1999) Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. 22, 168-170
21. Qu, T., Manev, R., and Manev, H. (2001) 5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. J. Neuropsychiatry Clin. Neurosci. 13, 304-305
22. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996) Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274, 99-102
23. Chen, X. S., Sheller, J. R., Johnson, E. N., and Funk, C. D. (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372, 179-182
24. Pratico, D., Lee, V. M. Y., Trojanowski, J. Q., Rokach, J., and Fitzgerald, G. A. (1998) Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 12, 1777-1783
25. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J. Q., and Lee, V. M. (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 21, 4183-4187
26. Uryu, K., Laurer, H., McIntosh, T., Pratico, D., Martinez, D., Leight, S., Lee, V. M., and Trojanowski, J. Q. (2002) Repetitive mild brain trauma accelerates Abeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. J. Neurosci. 22, 446-454
27. Sung, S., Yao, Y., Uryu, K., Yang, H., Lee, V. M., Trojanowski, J. Q., and Pratico, D. (2004) Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 18, 323-325
28. Suzuki, N., Cheung, T. T., Cai, X. D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264, 1336-1340
29. Kukar, T., Murphy, M. P., Eriksen, J. L., Sagi, S. A., Weggen, S., Smith, T. E., Ladd, T., Khan, M. A., Kache, R., Beard, J., Dodson, M., Merit, S., Ozols, V. V., Anastasiadis, P. Z., Das, P., Fauq, A., Koo, E. H., and Golde, T. E. (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med. 11, 545-550
30. Yagishita, S., Morishima-Kawashima, M., Tanimura, Y., Ishiura, S., and Ihara, Y. (2006) DAPT-induced intracellular accumulations of longer amyloid beta-proteins: further implications for the mechanism of intramembrane cleavage by gamma-secretase. Biochemistry 45, 3952-3960
31. Leissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., and Selkoe, D. J. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40, 1087-1093
32. Burkert, E., Szellas, D., Radmark, O., Steinhilber, D., and Werz, O. (2003) Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J. Leukoc. Biol. 73, 191-200
33. Qu, T., Uz, T., and Manev, H. (2000) Inflammatory 5-LOX mRNA and protein are increased in brain of aging rats. Neurobiol. Aging 21, 647-652
34. Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., and Ihara, Y. (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13, 45-53
35. Golde, T. E. (2003) Alzheimer disease therapy: can the amyloid cascade be halted? J. Clin. Invest. 111, 11-18
36. McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., Jansen, K., Delucia, M., Lin, W. L., Dolios, G., Wang, R., Eckman, C. B., Dickson, D. W., Hutton, M., Hardy, J., and Golde, T. (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199
37. Weggen, S., Eriksen, J. L., Das, P., Sagi, S. A., Wang, R., Pietrzik, C. U., Findlay, K. A., Smith, T. E., Murphy, M. P., Bulter, T., Kang, D. E., Marquez-Sterling, N., Golde, T. E., and Koo, E. H. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216
38. Eriksen, J. L., Sagi, S. A., Smith, T. E., Weggen, S., Das, P., McLendon, D. C., Ozols, V. V., Jessing, K. W., Zavitz, K. H., Koo, E. H., and Golde, T. E. (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest. 112, 440-449